

Title (en)

METHODS OF TREATING A DISEASE OR DISORDER ASSOCIATED WITH BRUTON'S TYROSINE KINASE

Title (de)

VERFAHREN ZUR BEHANDLUNG EINER KRANKHEIT ODER ERKRANKUNG IM ZUSAMMENHANG MIT BRUTON-TYROSINKINASE

Title (fr)

MÉTHODES DE TRAITEMENT D'UNE MALADIE OU D'UN TROUBLE ASSOCIÉ À LA TYROSINE KINASE DE BRUTON

Publication

**EP 2922827 A4 20160608 (EN)**

Application

**EP 13857254 A 20131119**

Priority

- US 201261728701 P 20121120
- US 201361870720 P 20130827
- US 2013070772 W 20131119

Abstract (en)

[origin: WO2014081712A2] The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.

IPC 8 full level

**C07D 239/48** (2006.01)

CPC (source: EP)

**A61K 31/4184** (2013.01); **A61K 31/505** (2013.01); **A61K 31/675** (2013.01); **A61K 31/7076** (2013.01); **A61K 39/3955** (2013.01); **A61K 45/06** (2013.01); **A61P 35/02** (2018.01); **A61K 2039/54** (2013.01); **A61K 2039/545** (2013.01)

C-Set (source: EP)

1. **A61K 31/7076 + A61K 2300/00**
2. **A61K 31/675 + A61K 2300/00**
3. **A61K 39/3955 + A61K 2300/00**
4. **A61K 31/4184 + A61K 2300/00**
5. **A61K 31/505 + A61K 2300/00**

Citation (search report)

- [X] WO 2011153514 A2 20111208 - PHARMACYCLICS INC [US], et al
- [XP] WO 2013063401 A1 20130502 - CELGENE AVIOMICS RES INC [US]
- [X] JAN A BURGER ET AL: "The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients", 1 November 2012 (2012-11-01), pages 187, XP002736107, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper47509.html>
- [XP] RAJENDRA N DAMLE ET AL: "Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR)", 15 April 2013 (2013-04-15), pages 3531, XP002736105, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8\_Supplement/3531.short> DOI: 10.1158/1538-7445.AM2013-3531

Citation (examination)

WO 2009158571 A1 20091230 - AVILA THERAPEUTICS AND USES TH [US], et al

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2014081712 A2 20140530**; **WO 2014081712 A3 20150716**; EP 2922827 A2 20150930; EP 2922827 A4 20160608; TW 201427667 A 20140716

DOCDB simple family (application)

**US 2013070772 W 20131119**; EP 13857254 A 20131119; TW 102142189 A 20131119